Dorzolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dorzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Dorzolamide is a topical carbonic anhydrase inhibitor originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but there are currently 0 clinical trials and 0 publications for this specific condition, so the prediction rests on the model score and mechanistic reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; ocular hypertension |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for dorzolamide were not available in the data compiled for this report. Based on known pharmacology, dorzolamide inhibits carbonic anhydrase II in the ciliary body. This reduces aqueous humor secretion and lowers intraocular pressure (IOP). Pharmacology data also list carbonic anhydrase 1, 7, 12 and 14 as targets.
Primary hereditary glaucoma is a genetically determined form of glaucoma in which elevated IOP drives optic nerve damage. Because the drug lowers IOP by reducing aqueous humor production, it is mechanistically plausible for this condition. The link is theoretical: the underlying cause of the hereditary form may differ from that of common open-angle glaucoma, and no study specific to this condition was found.
The model's other top-ranked predictions are not well supported. Most are hair-loss disorders (hypotrichosis, alopecia, alopecia areata), where no mechanistic link to carbonic anhydrase inhibition was identified. The two open-angle glaucoma predictions simply restate the drug's existing approved use. Of all the predictions, primary hereditary glaucoma is the most biologically coherent new indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN08880P | TRUSOPT OPHTHALMIC SOLUTION 2% | Solution | Santen Pharmaceutical Co., Ltd. Noto Plant |
| SIN14985P | ZOLICHEK EYE DROPS SOLUTION 2% | Solution, sterile | Indoco Remedies Limited |
| SIN14556P | DORZOLAMIDE AND TIMOLOL STADA EYE DROPS 20MG/5MG | Solution, sterile | Famar S.A. |
| SIN15435P | COSOPT-S OPHTHALMIC SOLUTION | Solution, sterile | Santen Pharmaceutical Co., Ltd. Noto Plant |
| SIN14984P | ZOLICHEK-T EYE DROPS SOLUTION | Solution, sterile | Indoco Remedies Limited |
All five registrations are currently valid. Approved indication text was not available for these products.
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): diabetes mellitus, diabetic ketoacidosis, myasthenia gravis and other neuromuscular junction diseases, hyperthyroidism (Graves disease, thyrotoxicosis), hypoglycemia, atrioventricular block, pulmonary emphysema and other bronchial disease, and anaphylaxis. Several of these are typical of beta-blocker components such as timolol in the combination products, so they may not apply to dorzolamide alone. They should be checked against the package insert.
Please refer to the package insert for the authoritative warnings, contraindications and drug interaction information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high and the IOP-lowering mechanism is plausible for hereditary glaucoma. However, no trials or publications support this specific indication, so it is a model prediction only (L5). Dorzolamide is already marketed in Singapore for open-angle glaucoma and ocular hypertension, so the new indication adds value only if evidence shows benefit in hereditary forms.
To proceed, the following is needed:
- A targeted literature search for dorzolamide or carbonic anhydrase inhibitors in primary congenital and juvenile hereditary glaucoma, including pediatric studies
- The HSA package insert, to confirm warnings, contraindications and approved indications
- Detailed mechanism of action data (MOA)
- Clinical input on whether hereditary glaucoma subtypes respond to aqueous suppressants, and on pediatric safety
- A prospective study design, if the clinical rationale holds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.